Cargando…

Favourable outcome of multisystem venous thrombosis associated with novel SERPINC1 mutation after treated with dabigatran: a case report with 7-year follow-up

BACKGROUND: Mutations in SERPINC1 lead to deficiency in antithrombin (AT) which is an endogenous anticoagulant of normal hemostasis and could result in venous thromboembolism (VTE). CASE PRESENTATION: A 61-year-old male patient with recurrent thrombosis returned to the hospital with multiple cerebra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Teng, Liu, Yu, Jiang, Xiaofeng, Zhang, Wei, Zhou, Honglian, Hu, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798687/ https://www.ncbi.nlm.nih.gov/pubmed/36578065 http://dx.doi.org/10.1186/s12959-022-00446-3

Ejemplares similares

Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency
por: Zeng, Wei, et al.
Publicado: (2017)

Correction: Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency
por: Zeng, Wei, et al.
Publicado: (2018)

Argatroban Resistance and Successful Adjunctive Anticoagulation for Cerebral Venous Sinus Thrombosis With SERPINC1 Mutation: A Case Report
por: Ma, Hongrui, et al.
Publicado: (2023)

A novel variation of SERPINC1 caused deep venous thrombosis in a Chinese family: A case report
por: Peng, Yu, et al.
Publicado: (2019)

CBS and SERPINC1 mutation-induced ischemic stroke and multisystem diseases in a young woman: a case description and literature analysis
por: Jiang, Xuanfei, et al.
Publicado: (2023)

Identification and characterization of two SERPINC1 mutations causing congenital antithrombin deficiency
por: Wang, Han-lu, et al.
Publicado: (2023)

Case report: A case of new mutation in SERPINC1 leading to thrombotic microangiopathy
por: Li, Bing, et al.
Publicado: (2023)

A Case of Treatment With Dabigatran for Cerebral Venous Thrombosis Caused by Hereditary Protein C Deficiency
por: Fukushima, Taiki, et al.
Publicado: (2021)

Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
por: Kellermair, Lukas, et al.
Publicado: (2022)

Inherited antithrombin deficiency caused by a mutation in the SERPINC1 gene: A case report
por: Hou, Xinwei, et al.
Publicado: (2022)

Missense mutation of SERPINC1 (p.Ser426Leu) in a young patient presenting as refractory and recurrent venous thromboembolism: A case report
por: Yu, Haixu, et al.
Publicado: (2022)

SerpinC1/Antithrombin III in kidney-related diseases
por: Lu, Zeyuan, et al.
Publicado: (2017)

New genetic variant in the SERPINC1 gene: hereditary Antithrombin deficiency case report, familial thrombosis and considerations on genetic counseling
por: Polyak, Margarita E., et al.
Publicado: (2020)

Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency
por: Toderici, Mara, et al.
Publicado: (2016)

Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial
por: Song, Runze, et al.
Publicado: (2021)

Correction: Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency
por: Toderici, Mara, et al.
Publicado: (2016)

Novel Mutation p.Asp374Val of SERPINC1 in a Turkish Family with Inherited Antithrombin Deficiency
por: Aslan, Deniz
Publicado: (2021)

Antithrombin Deficiency Is Associated with a Novel Homozygous Detrimental Mutation in SERPINC1 Gene in a Saudi Female
por: Alqarni, Sana, et al.
Publicado: (2023)

Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
por: Kim, Seondeuk, et al.
Publicado: (2022)

Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data
por: van Leent, Merlijn W. J., et al.
Publicado: (2015)

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial
por: Ferro, José M., et al.
Publicado: (2019)

Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
por: Brandão, Leonardo R., et al.
Publicado: (2022)

Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism
por: Ogbonna, Kelechi C, et al.
Publicado: (2015)

Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report
por: Sun, Huan, et al.
Publicado: (2018)

Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury
por: Wang, Feng, et al.
Publicado: (2015)

Global Thrombosis Test – a possible monitoring system for the effects and safety of dabigatran
por: Otsui, Kazunori, et al.
Publicado: (2015)

Acquired SERPINC1/antithrombin deficiency during oral contraceptive consumption: a case report
por: Denora, D., et al.
Publicado: (2023)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Patients with SERPINC1 rs2227589 polymorphism found to have multiple cerebral venous sinus thromboses despite a normal antithrombin level: A case report
por: Liao, Feng, et al.
Publicado: (2022)

Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran
por: Fanola, Christina L
Publicado: (2015)

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran
por: Leung, Timothy S, et al.
Publicado: (2015)

Association of SERPINC1 Gene Polymorphism (rs2227589) With Pulmonary Embolism Risk in a Chinese Population
por: Yue, Yongjian, et al.
Publicado: (2019)

Urine SERPINC1/ORM1 as biomarkers for early detection of lupus nephritis in MRL-lpr mice
por: Kim, Young-Eun, et al.
Publicado: (2023)

Carotid Thromboembolism Associated with Nephrotic Syndrome Treated with Dabigatran
por: Sasaki, Yosuke, et al.
Publicado: (2014)

Recent advances in understanding, diagnosing and treating venous thrombosis
por: Chan, Noel C, et al.
Publicado: (2020)

The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Venous Thrombosis
Publicado: (1901)

Venous Thrombosis
por: Mitchell, J. R. A.
Publicado: (1988)

Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
por: Stevanović, J., et al.
Publicado: (2016)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k1cpmnj1qocuvapk1f6r51nkmh